Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan - Concepedia

Concepedia

Publication | Closed Access

Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan

44

Citations

13

References

2015

Year

Takashi Taga, Tomoyuki Watanabe, Daisuke Tomizawa, Kazuko Kudo, Kiminori Terui, Hiroshi Moritake, Akitoshi Kinoshita, Shotaro Iwamoto, Hideki Nakayama, Hiroyuki Takahashi,

Pediatric Blood & Cancer

Abstract

The attempt of risk-oriented prospective study for ML-DS was unsuccessful, but despite the dose reduction of chemotherapeutic agents, the overall outcome was good, and further dose reduction might be possible for specific subgroups.

References

	Year	Citations
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity Ursula Creutzig, Dirk Reinhardt, S. Diekamp, Leukemia Down SyndromeHematologyAml PatientsDose IntensityPharmacotherapy	2005	202
Increased Age at Diagnosis Has a Significantly Negative Effect on Outcome in Children With Down Syndrome and Acute Myeloid Leukemia: A Report From the Children’s Cancer Group Study 2891 Alan S. Gamis, William G. Woods, Todd A. Alonzo, Journal of Clinical Oncology	2003	161
Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL Qiang Wen, Benjamin Goldenson, Serena J. Silver, Cell Cell RegulationReceptor Tyrosine KinaseImmunologyCell ProliferationMedicine	2012	150
Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy Metodi V. Stankov, Mona El Khatib, Basant Kumar Thakur, Leukemia	2013	118
Treatment for myeloid leukaemia of Down syndrome: population‐based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials Anupama Rao, Robert K. Hills, Charles Stiller, British Journal of Haematology Mixed-phenotype Acute LeukemiaPathologyAml 12Myeloid LeukaemiaDs Children	2005	101
Prospective Study of a Pirarubicin, Intermediate-Dose Cytarabine, and Etoposide Regimen in Children With Down Syndrome and Acute Myeloid Leukemia: The Japanese Childhood AML Cooperative Study Group Kazuko Kudo, Seiji Kojima, Ken Tabuchi, Journal of Clinical Oncology	2007	97
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced‐dose chemotherapy on Children's Oncology Group trial A2971 April Sorrell, Todd A. Alonzo, Joanne M. Hilden, Cancer	2012	80
Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome Takashi Taga, Akiko Saito, Kazuko Kudo, Blood	2012	58
Long‐term results of an ultra low‐dose cytarabine‐based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome Ali Alahmari, Niketa C. Shah, Lillian Sung, British Journal of Haematology Down SyndromeHematological MalignancyTreatment IntensityPediatric HematologyMedicine	2006	55
Continuous and high‐dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study Takashi Taga, Yasuto Shimomura, Yasuo Horikoshi, Pediatric Blood & Cancer	2010	37

Page 1